{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:29:20Z","timestamp":1791811760850,"version":"4.3.4"},"reference-count":463,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health (NIH) grants","award":["R01AI150668"],"award-info":[{"award-number":["R01AI150668"]}]},{"name":"National Institutes of Health (NIH) grants","award":["RO1DK107713"],"award-info":[{"award-number":["RO1DK107713"]}]},{"name":"National Institutes of Health (NIH) grants","award":["R21AI110685"],"award-info":[{"award-number":["R21AI110685"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Pseudomonas aeruginosa is an important Gram-negative opportunistic pathogen which causes many severe acute and chronic infections with high morbidity, and mortality rates as high as 40%. What makes P. aeruginosa a particularly challenging pathogen is its high intrinsic and acquired resistance to many of the available antibiotics. In this review, we review the important acute and chronic infections caused by this pathogen. We next discuss various animal models which have been developed to evaluate P. aeruginosa pathogenesis and assess therapeutics against this pathogen. Next, we review current treatments (antibiotics and vaccines) and provide an overview of their efficacies and their limitations. Finally, we highlight exciting literature on novel antibiotic-free strategies to control P. aeruginosa infections.<\/jats:p>","DOI":"10.3390\/cells12010199","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T02:15:42Z","timestamp":1672798542000},"page":"199","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":250,"title":["Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1306-1027","authenticated-orcid":false,"given":"Stephen J.","family":"Wood","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, & Cell Therapy, Rush University Medical Center, Chicago, IL 60612, USA"},{"name":"Department of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7523-2397","authenticated-orcid":false,"given":"Timothy M.","family":"Kuzel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, & Cell Therapy, Rush University Medical Center, Chicago, IL 60612, USA"},{"name":"Cancer Center, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1755-9997","authenticated-orcid":false,"given":"Sasha H.","family":"Shafikhani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, & Cell Therapy, Rush University Medical Center, Chicago, IL 60612, USA"},{"name":"Department of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, IL 60612, USA"},{"name":"Cancer Center, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"key":"ref_1","first-page":"1109","article-title":"Pseudomonas, Burkholderia and related genera","volume":"2","author":"Pitt","year":"1998","journal-title":"Microbiol. Microb. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S775","DOI":"10.1093\/clinids\/6.Supplement_3.S775","article-title":"Classics in infectious diseases. On the blue and green coloration that appears on bandages. By Carle Gessard (1850\u20131925)","volume":"6","author":"Gessard","year":"1984","journal-title":"Rev. Infect. Dis."},{"key":"ref_3","first-page":"65","article-title":"Des races du bacille pyocyanique","volume":"5","author":"Gessard","year":"1891","journal-title":"Ann. Inst. Pasteur"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1164\/ajrccm\/144.5.1147","article-title":"Role of mechanical injury on airway surface in the pathogenesis of Pseudomonas aeruginosa","volume":"144","author":"Yamaguchi","year":"1991","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1165\/ajrcmb\/5.3.242","article-title":"Wound repair of human surface respiratory epithelium","volume":"5","author":"Zahm","year":"1991","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1183\/09031936.94.07101746","article-title":"Interaction of Pseudomonas aeruginosa with human respiratory mucosa in vitro","volume":"7","author":"Tsang","year":"1994","journal-title":"Eur. Respir. J."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Mohamed, M.F., Gupta, K., Goldufsky, J.W., Roy, R., Kuzel, T.M., Reiser, J., and Shafikhani, S.H. CrkII\/Abl Phosphorylation Cascade Is Critical for NLRC4 Inflammasome Activity and Is Blocked by Pseudomonas ExoT. Nat. Commun., 2022. in press.","DOI":"10.1038\/s41467-022-28967-5"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Roy, R., Zayas, J., Singh, S.K., Delgado, K., Wood, S.J., Mohamed, M.F., Frausto, D.M., Estupinian, R., Giurini, E.F., and Kuzel, T.M. (2022). Overriding impaired FPR chemotaxis signaling in diabetic neutrophil stimulates infection control in murine diabetic wound. eLife, 11.","DOI":"10.7554\/eLife.72071"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/wrr.12310","article-title":"Pseudomonas aeruginosa uses T3SS to inhibit diabetic wound healing","volume":"23","author":"Goldufsky","year":"2015","journal-title":"Wound Repair Regen."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1164\/ajrccm\/154.4_Pt_2.S155","article-title":"Receptors in the Pseudomonas aeruginosa adherence to injured and repairing airway epithelium","volume":"154","author":"Plotkowski","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1699-0463.1996.tb04955.x","article-title":"Bacterial colonization and healing of venous leg ulcers","volume":"104","author":"Madsen","year":"1996","journal-title":"Acta Pathol. Microbiol. Immunol. Scand."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1440-0960.1992.tb00083.x","article-title":"The effect of bacterial colonization on venous ulcer healing","volume":"33","author":"Halbert","year":"1992","journal-title":"Australas. J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1742-481X.2006.00159.x","article-title":"Multiple bacterial species reside in chronic wounds: A longitudinal study","volume":"3","author":"Gjodsbol","year":"2006","journal-title":"Int. Wound J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1099\/jmm.0.46005-0","article-title":"Genotypic and phenotypic characteristics of Pseudomonas aeruginosa isolates associated with ulcerative keratitis","volume":"54","author":"Winstanley","year":"2005","journal-title":"J. Med. Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1099\/ijs.0.64780-0","article-title":"Valid publication of names of prokaryotes according to the rules of nomenclature: Past history and current practice","volume":"56","author":"Tindall","year":"2006","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"ref_16","unstructured":"Jessen, O. (1965). Pseudomonas aeruginosa and Other Green Fluorescent Pseudomonads: A Taxonomic Study, Munksgaard."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/35023079","article-title":"Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen","volume":"406","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/gb-2006-7-10-r90","article-title":"Genomic analysis reveals that Pseudomonas aeruginosa virulence is combinatorial","volume":"7","author":"Lee","year":"2006","journal-title":"Genome Biol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Roy, P.H., Tetu, S.G., Larouche, A., Elbourne, L., Tremblay, S., Ren, Q., Dodson, R., Harkins, D., Shay, R., and Watkins, K. (2010). Complete genome sequence of the multiresistant taxonomic outlier Pseudomonas aeruginosa PA7. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0008842"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0723-2020(96)80025-7","article-title":"Fatty acid content in whole-cell hydrolysates and phospholipid and phospholipid fractions of Pseudomonads: A taxonomic evaluation","volume":"19","author":"Vancanneyti","year":"1996","journal-title":"Syst. Appl. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diagmicrobio.2006.11.007","article-title":"Rapid and accurate detection of Pseudomonas aeruginosa by real-time polymerase chain reaction with melting curve analysis targeting gyrB gene","volume":"58","author":"Motoshima","year":"2007","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_22","first-page":"939","article-title":"Pseudomonas aeruginosa\u2014Its Characterization and Identification","volume":"5","author":"Haynes","year":"1951","journal-title":"Microbiology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S1286-4579(00)01259-4","article-title":"Establishment of Pseudomonas aeruginosa infection: Lessons from a versatile opportunist","volume":"2","author":"Lyczak","year":"2000","journal-title":"Microbes Infect"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Valot, B., Guyeux, C., Rolland, J.Y., Mazouzi, K., Bertrand, X., and Hocquet, D. (2015). What it takes to be a Pseudomonas aeruginosa? The core genome of the opportunistic pathogen updated. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126468"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wood, S.J., Goldufsky, J.W., Dorafshar, A.H., and Shafikhani, S.H. Pseudomonas aeruginosa Cytotoxins: Mechanisms of Cytotoxicity and Impact on Inflammatory Responses. Cells, 2023. in press.","DOI":"10.3390\/cells12010195"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3389\/fmicb.2015.01036","article-title":"Clinical utilization of genomics data produced by the international Pseudomonas aeruginosa consortium","volume":"6","author":"Freschi","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/2049-632X.12033","article-title":"Pseudomonas aeruginosa: New insights into pathogenesis and host defenses","volume":"67","author":"Gellatly","year":"2013","journal-title":"Pathog. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1534-5807(02)00295-2","article-title":"Pseudomonas aeruginosa anaerobic respiration in biofilms: Relationships to cystic fibrosis pathogenesis","volume":"3","author":"Yoon","year":"2002","journal-title":"Dev. Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1099\/00221287-142-9-2333","article-title":"Environmental gasoline-utilizing isolates and clinical isolates of Pseudomonas aeruginosa are taxonomically indistinguishable by chemotaxonomic and molecular techniques","volume":"142","author":"Foght","year":"1996","journal-title":"Microbiology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S627","DOI":"10.1093\/clinids\/6.Supplement_3.S627","article-title":"Epidemiology of infections due to Pseudomonas aeruginosa","volume":"6","author":"Morrison","year":"1984","journal-title":"Rev. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1365-2133.2008.08437.x","article-title":"Skin microbiota: A source of disease or defence?","volume":"158","author":"Cogen","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_32","first-page":"521","article-title":"Community-acquired Pseudomonas aeruginosa pneumonia associated with the use of a home humidifier","volume":"141","author":"Harris","year":"1984","journal-title":"West. J. Med."},{"key":"ref_33","unstructured":"Mandell, G.L., Dolin, R., and Bennett, J.E. (1995). Pseudomonas aeruginosa. Principles and Practices of Infectious Diseases, Churchill Livingstone."},{"key":"ref_34","first-page":"237","article-title":"Endogenous and exogenous infection with Pseudomonas aeruginosa in a burns unit","volume":"66","author":"Chitkara","year":"1981","journal-title":"Int. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00000637-198907000-00007","article-title":"The effect of endogenous skin bacteria on burn wound infection","volume":"23","author":"Phillips","year":"1989","journal-title":"Ann. Plast. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ppul.10135","article-title":"Early infection and progression of cystic fibrosis lung disease","volume":"34","author":"Koch","year":"2002","journal-title":"Pediatr. Pulmonol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Hauser, A., and Rello, J. (2003). Molecular pathogenesis of acute Pseudomonas aeruginosa infections. Severe Infections Caused by Pseudomonas aeruginosa, Kluwer Academic\/Plenum Press.","DOI":"10.1007\/978-1-4615-0433-7"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/archsurg.137.12.1353","article-title":"Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care","volume":"137","author":"Harbarth","year":"2002","journal-title":"Arch. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1378\/chest.125.2.607","article-title":"Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa","volume":"125","author":"Osmon","year":"2004","journal-title":"Chest"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e00019-18","DOI":"10.1128\/CMR.00019-18","article-title":"Epidemiology, biology, and impact of clonal Pseudomonas aeruginosa infections in cystic fibrosis","volume":"31","author":"Parkins","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1590\/0037-8682-0506-2017","article-title":"Mortality in patients with multidrug-resistant Pseudomonas aeruginosa infections: A meta-analysis","volume":"51","author":"Matos","year":"2018","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref_42","first-page":"823","article-title":"Serious Pseudomonas aeruginosa infection in AIDS","volume":"7","author":"Shepp","year":"1994","journal-title":"J. Acq. Immun. Defic. Synd."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/clinids\/14.2.403","article-title":"Life-threatening Pseudomonas aeruginosa infections in patients with human immunodeficiency virus infection","volume":"14","author":"Kielhofner","year":"1992","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"ref_45","unstructured":"(2022, November 01). Antibiotic Resistance Threats in the United States, Available online: https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/jms.jms_25_17","article-title":"World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","volume":"32","author":"Shrivastava","year":"2018","journal-title":"J. Med. Soc."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Rice, L.B. (2008). Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE, The University of Chicago Press.","DOI":"10.1086\/533452"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jama.289.7.885","article-title":"Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use","volume":"289","author":"Neuhauser","year":"2003","journal-title":"JAMA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1378\/chest.128.6.3854","article-title":"Epidemiology and outcomes of health-care\u2013associated pneumonia: Results from a large US database of culture-positive pneumonia","volume":"128","author":"Kollef","year":"2005","journal-title":"Chest J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1164\/rccm.200408-1044SO","article-title":"Pathogen-host interactions in Pseudomonas aeruginosa pneumonia","volume":"171","author":"Sadikot","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/ajrccm.157.3.9703014","article-title":"Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: Relapse or reinfection?","volume":"157","author":"Rello","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1017\/S0950268800052109","article-title":"Epidemiology of Pseudomonas aeruginosa keratitis in contact lens wearers","volume":"114","author":"Stapleton","year":"1995","journal-title":"Epidemiol. Infect."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0002-9394(69)93156-0","article-title":"Pseudomonas aeruginosa keratitis: Mixed infections of the eye","volume":"67","author":"Burns","year":"1969","journal-title":"Am. J. Ophthalmol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e00355-19","DOI":"10.1128\/AAC.00355-19","article-title":"The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program","volume":"63","author":"Diekema","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Montero, M.M., L\u00f3pez Montesinos, I., Knobel, H., Molas, E., Sorl\u00ed, L., Siverio-Par\u00e9s, A., Prim, N., Segura, C., Duran-Jord\u00e0, X., and Grau, S. (2020). Risk factors for mortality among patients with Pseudomonas aeruginosa bloodstream infections: What is the influence of XDR phenotype on outcomes?. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020514"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/cid\/ciz223","article-title":"Antibiotic therapy for Pseudomonas aeruginosa bloodstream infections: How long is long enough?","volume":"69","author":"Fabre","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/infdis\/151.2.291","article-title":"Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa","volume":"151","author":"Norden","year":"1985","journal-title":"J. Infect. Dis."},{"key":"ref_58","first-page":"2413","article-title":"Diagnosis and management of osteomyelitis","volume":"63","author":"Carek","year":"2001","journal-title":"Am. Fam. Physician"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/clinids\/5.2.314","article-title":"Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa","volume":"5","author":"Reyes","year":"1983","journal-title":"Rev. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jmii.2014.08.019","article-title":"Pseudomonas aeruginosa infective endocarditis in patients who do not use intravenous drugs: Analysis of risk factors and treatment outcomes","volume":"49","author":"Lin","year":"2016","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1086\/653053","article-title":"Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"51","author":"Jones","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"448","DOI":"10.5507\/bp.2016.014","article-title":"Epidemiology of hospital-acquired pneumonia: Results of a Central European multicenter, prospective, observational study compared with data from the European region","volume":"160","author":"Herkel","year":"2016","journal-title":"Biomed. Pap."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/j.jtcvs.2014.07.107","article-title":"Ventilator-associated pneumonia after cardiac surgery: A meta-analysis and systematic review","volume":"148","author":"He","year":"2014","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1164\/rccm.201102-0349OC","article-title":"High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia","volume":"184","author":"Chung","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijid.2016.06.014","article-title":"Prevalence of Pseudomonas aeruginosa and antimicrobial-resistant Pseudomonas aeruginosa in patients with pneumonia in mainland China: A systematic review and meta-analysis","volume":"49","author":"Ding","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s00134-013-2828-9","article-title":"Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients","volume":"39","author":"Tumbarello","year":"2013","journal-title":"Intensive Care Med."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Duszynska, W., Idziak, M., Smardz, K., Burkot, A., Grotowska, M., and Rojek, S. (2022). Frequency, Etiology, Mortality, Cost, and Prevention of Respiratory Tract Infections\u2014Prospective, One Center Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133764"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/00003246-200203000-00005","article-title":"Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa","volume":"30","author":"Hauser","year":"2002","journal-title":"Crit. Care Med."},{"key":"ref_69","first-page":"7","article-title":"Pseudomonas aeruginosa ventilator-associated pneumonia management","volume":"9","author":"Borgatta","year":"2016","journal-title":"Infect. Drug Resist."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1517\/14656566.2014.914172","article-title":"Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: Current and emerging therapeutic approaches","volume":"15","author":"Karaiskos","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0891-5520(05)70209-9","article-title":"Hospital-acquired pneumonia: Epidemiology, etiology, and treatment","volume":"12","author":"McEachern","year":"1998","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Teweldemedhin, M., Gebreyesus, H., Atsbaha, A.H., Asgedom, S.W., and Saravanan, M. (2017). Bacterial profile of ocular infections: A systematic review. BMC Ophthalmol., 17.","DOI":"10.1186\/s12886-017-0612-2"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1136\/bjophthalmol-2018-312881","article-title":"Queensland microbial keratitis database: 2005\u20132015","volume":"103","author":"Green","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1038\/s41433-020-01378-w","article-title":"Infectious keratitis: Trends in microbiological and antibiotic sensitivity patterns","volume":"35","author":"Soleimani","year":"2021","journal-title":"Eye"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/ICO.0b013e318156caf2","article-title":"Risk factors and causative organisms in microbial keratitis","volume":"27","author":"Green","year":"2008","journal-title":"Cornea"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2021.02.024","article-title":"Comparison of Clinical Features and Treatment Outcomes of Pseudomonas aeruginosa Keratitis in Contact Lens and Non\u2013Contact Lens Wearers","volume":"227","author":"Enzor","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1056\/NEJM196507292730524","article-title":"Pseudomonas aeruginosa urinary-tract infection","volume":"273","author":"Shirley","year":"1965","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.juro.2011.09.035","article-title":"Pseudomonas aeruginosa urinary tract infection in children: Risk factors and outcomes","volume":"187","author":"Bitsori","year":"2012","journal-title":"J. Urol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Newman, J.W., Floyd, R.V., and Fothergill, J.L. (2017). The contribution of Pseudomonas aeruginosa virulence factors and host factors in the establishment of urinary tract infections. FEMS Microbiol. Lett., 364.","DOI":"10.1093\/femsle\/fnx124"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0924-8579(00)00359-9","article-title":"Catheter-associated urinary tract infections","volume":"17","author":"Warren","year":"2001","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1001\/archinte.1996.00440170139015","article-title":"Epidemiology and Outcome of Pseudomonas aeruginosa Bacteremia, With Special Emphasis on the Influence of Antibiotic Treatment","volume":"156","author":"Vidal","year":"1996","journal-title":"Arch. Intern. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jinf.2014.08.012","article-title":"Bacteremia is associated with excess long-term mortality: A 12-year population-based cohort study","volume":"70","author":"Nielsen","year":"2015","journal-title":"J. Infect."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e02671-16","DOI":"10.1128\/AAC.02671-16","article-title":"Results from a 13-year prospective cohort study show increased mortality associated with bloodstream infections caused by Pseudomonas aeruginosa compared to other bacteria","volume":"61","author":"Thaden","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Dalager-Pedersen, M., S\u00f8gaard, M., Sch\u00f8nheyder, H.C., Thomsen, R.W., Baron, J.A., and Nielsen, H. (2014). Venous thromboembolism after community-acquired bacteraemia: A 20-year Danish cohort study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086094"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.113.006699","article-title":"Risk for myocardial infarction and stroke after community-acquired bacteremia: A 20-year population-based cohort study","volume":"129","author":"Nielsen","year":"2014","journal-title":"Circulation"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jinf.2004.04.004","article-title":"Profile and prognosis of febrile elderly patients with bacteremic urinary tract infection","volume":"50","author":"Tal","year":"2005","journal-title":"J. Infect."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jpeds.2017.04.045","article-title":"Neurocognitive outcomes at 10 years of age in extremely preterm newborns with late-onset bacteremia","volume":"187","author":"Bright","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3390\/pathogens3030680","article-title":"Pseudomonas aeruginosa diversification during infection development in cystic fibrosis lungs\u2014A review","volume":"3","author":"Sousa","year":"2014","journal-title":"Pathogens"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.tim.2016.01.008","article-title":"Pseudomonas aeruginosa evolutionary adaptation and diversification in cystic fibrosis chronic lung infections","volume":"24","author":"Winstanley","year":"2016","journal-title":"Trends Microbiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/cid\/civ377","article-title":"Impact of sustained eradication of new Pseudomonas aeruginosa infection on long-term outcomes in cystic fibrosis","volume":"61","author":"Kloster","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jama.293.5.581","article-title":"Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis","volume":"293","author":"Li","year":"2005","journal-title":"JAMA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.dsx.2013.02.006","article-title":"The diabetic foot infections: Biofilms and antimicrobial resistance","volume":"7","author":"Malik","year":"2013","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00125-010-1893-7","article-title":"Changing microbiological profile of pathogenic bacteria in diabetic foot infections: Time for a rethink on which empirical therapy to choose?","volume":"54","author":"Ramakant","year":"2011","journal-title":"Diabetologia"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1046\/j.1464-5491.2002.00696_1.x","article-title":"Microbiological profile of infected diabetic foot ulcers","volume":"19","author":"Ge","year":"2002","journal-title":"Diabet. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1524-475X.2007.00321.x","article-title":"Biofilms in chronic wounds","volume":"16","author":"James","year":"2008","journal-title":"Wound Repair Regen."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Dowd, S.E., Sun, Y., Secor, P.R., Rhoads, D.D., Wolcott, B.M., James, G.A., and Wolcott, R.D. (2008). Survey of bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing. BMC Microbiol., 8.","DOI":"10.1186\/1471-2180-8-43"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ejim.2005.06.016","article-title":"Bacterial etiology of diabetic foot infections in South India","volume":"16","author":"Shankar","year":"2005","journal-title":"Eur. J. Intern. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/infdis\/jit005","article-title":"Quantitation and composition of cutaneous microbiota in diabetic and nondiabetic men","volume":"207","author":"Redel","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1099\/jmm.0.000003","article-title":"Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines","volume":"64","author":"Goldufsky","year":"2015","journal-title":"J. Med. Microbiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1524-475X.2007.00283.x","article-title":"Why chronic wounds will not heal: A novel hypothesis","volume":"16","author":"Bjarnsholt","year":"2008","journal-title":"Wound Repair Regen."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1464-5491.2001.00422.x","article-title":"The effects of ulcer size and site, patient\u2019s age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers","volume":"18","author":"Oyibo","year":"2001","journal-title":"Diabet. Med."},{"key":"ref_102","first-page":"37","article-title":"A rat model of diabetic wound infection for the evaluation of topical antimicrobial therapies","volume":"62","author":"Mendes","year":"2012","journal-title":"Comp. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1524-475X.2010.00608.x","article-title":"Delayed wound healing in diabetic (db\/db) mice with Pseudomonas aeruginosa biofilm challenge: A model for the study of chronic wounds","volume":"18","author":"Zhao","year":"2010","journal-title":"Wound Repair Regen."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1524-475X.2012.00793.x","article-title":"Time course study of delayed wound healing in a biofilm-challenged diabetic mouse model","volume":"20","author":"Zhao","year":"2012","journal-title":"Wound Repair Regen."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1046\/j.1462-5822.2001.00107.x","article-title":"Pseudomonas aeruginosa ExoT inhibits in vitro lung epithelial wound repair","volume":"3","author":"Geiser","year":"2001","journal-title":"Cell Microbiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/IAI.72.1.546-558.2004","article-title":"The ADP ribosyltransferase domain of Pseudomonas aeruginosa ExoT contributes to its biological activities","volume":"72","author":"Shafikhani","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/oxfordjournals.aje.a009606","article-title":"Neutropenia is a risk factor for gram-negative bacillus bacteremia in human immunodeficiency virus-infected patients: Results of a nested case-control study","volume":"148","author":"Mathews","year":"1998","journal-title":"Am. J. Epidemiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fcimb.2013.00115","article-title":"Pathogenesis of intestinal Pseudomonas aeruginosa infection in patients with cancer","volume":"3","author":"Markou","year":"2014","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1378\/chest.117.4.1017","article-title":"Bacterial pneumonia in hospitalized patients with HIV infection: The Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study","volume":"117","author":"Afessa","year":"2000","journal-title":"Chest"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1007626410724","article-title":"Pseudomonas spp. complications in patients with HIV disease: An eight-year clinical and microbiological survey","volume":"16","author":"Manfredi","year":"2000","journal-title":"Eur. J. Epidemiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0163-4453(99)90247-5","article-title":"Pseudomonas aeruginosa infection in human immunodeficiency virus infected patients","volume":"38","author":"Meynard","year":"1999","journal-title":"J. Infect."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/clinids\/23.3.641","article-title":"Prolonged efficiency of secondary prophylaxis with colistin aerosols for respiratory infection due to Pseudomonas aeruginosa in patients infected with human immunodeficiency virus","volume":"23","author":"Zylberberg","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"ref_113","first-page":"692","article-title":"The spectrum of bronchopulmonary infection caused by Pseudomonas aeruginosa in patients infected with the human immunodeficiency virus","volume":"196","year":"1996","journal-title":"Rev. Clin. Esp."},{"key":"ref_114","first-page":"73","article-title":"Bronchopulmonary infection with Pseudomonas aeruginosa in patients infected with human immunodeficiency virus","volume":"71","author":"Ali","year":"1995","journal-title":"Genitourin. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s15010-013-0525-9","article-title":"The current spectrum of infection in cancer patients with chemotherapy related neutropenia","volume":"42","author":"Nesher","year":"2014","journal-title":"Infection"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/postgradmedj\/79.938.691","article-title":"Pneumonia due to antibiotic resistant Streptococcus pneumoniae and Pseudomonas aeruginosa in the HAART era","volume":"79","author":"Allen","year":"2003","journal-title":"Postgrad. Med. J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1164\/rccm.201603-0523OC","article-title":"Immune response and mortality risk relate to distinct lung microbiomes in patients with HIV and pneumonia","volume":"195","author":"Shenoy","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/aid.2013.0198","article-title":"Metabolomics of bronchoalveolar lavage differentiate healthy HIV-1-infected subjects from controls","volume":"30","author":"Cribbs","year":"2014","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Paprocka, P., Durna\u015b, B., Ma\u0144kowska, A., Kr\u00f3l, G., Wollny, T., and Bucki, R. (2022). Pseudomonas aeruginosa infections in cancer patients. Pathogens, 11.","DOI":"10.3390\/pathogens11060679"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s100960050326","article-title":"Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1","volume":"18","author":"Vidal","year":"1999","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/107327480301000507","article-title":"Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin\u2019s lymphoma","volume":"10","author":"Chrischilles","year":"2003","journal-title":"Cancer Control"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/resp.12848","article-title":"Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients","volume":"21","author":"Gudiol","year":"2016","journal-title":"Respirology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jinf.2014.05.018","article-title":"Bloodstream infections in neutropenic patients with cancer: Differences between patients with haematological malignancies and solid tumours","volume":"69","author":"Marin","year":"2014","journal-title":"J. Infect."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archinte.160.4.501","article-title":"Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes","volume":"160","author":"Chatzinikolaou","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.2169\/internalmedicine.37.1014","article-title":"Changes in the incidence and etiological patterns of bacteremia associated with acute leukemia over a 25-year period","volume":"37","author":"Funada","year":"1998","journal-title":"Intern. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2147\/IDR.S163979","article-title":"Epidemiology, susceptibility, and risk factors for acquisition of MDR\/XDR Gram-negative bacteria among kidney transplant recipients with urinary tract infections","volume":"11","author":"Yuan","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/21505594.2016.1139279","article-title":"Bloodstream infections after solid-organ transplantation","volume":"7","author":"Kritikos","year":"2016","journal-title":"Virulence"},{"key":"ref_130","first-page":"509","article-title":"A clinical analysis of 96 patients with bloodstream infections after solid organ transplantation","volume":"37","author":"Wan","year":"2012","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1111\/j.1600-6143.2007.01964.x","article-title":"Bloodstream infections among transplant recipients: Results of a Nationwide Surveillance in Spain 1","volume":"7","author":"Moreno","year":"2007","journal-title":"Am. J. Transplant."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1086\/646987","article-title":"Comparative risk of bloodstream infection in organ transplant recipients","volume":"15","author":"McClean","year":"1994","journal-title":"Infect. Control. Hosp. Epidemiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/lt.22296","article-title":"Spectrum of early-onset and late-onset bacteremias after liver transplantation: Implications for management","volume":"17","author":"Lee","year":"2011","journal-title":"Liver Transplant."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1097\/00007890-200006150-00025","article-title":"Significance of blood stream infection after lung transplantation: Analysis in 176 consecutive patients1","volume":"69","author":"Palmer","year":"2000","journal-title":"Transplantation"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1093\/cid\/ciz1113","article-title":"Burden and timeline of infectious diseases in the first year after solid organ transplantation in the Swiss Transplant Cohort Study","volume":"71","author":"Stampf","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/tid.12278","article-title":"Frequency and clinical outcomes of ESKAPE bacteremia in solid organ transplantation and the risk factors for mortality","volume":"16","author":"Ye","year":"2014","journal-title":"Transpl. Infect. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e003845","DOI":"10.1136\/bmjopen-2013-003845","article-title":"Burn injury, gender and cancer risk: Population-based cohort study using data from Scotland and Western Australia","volume":"4","author":"Duke","year":"2014","journal-title":"BMJ Open"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Fear, V.S., Boyd, J.H., Rea, S., Wood, F.M., Duke, J.M., and Fear, M.W. (2017). Burn injury leads to increased long-term susceptibility to respiratory infection in both mouse models and population studies. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169302"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0039-6109(16)42643-5","article-title":"The immune consequences of trauma","volume":"62","author":"Miller","year":"1982","journal-title":"Surg. Clin. N. Am."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.12998\/wjcc.v9.i10.2228","article-title":"Distribution and drug resistance of pathogens in burn patients in China from 2006 to 2019","volume":"9","author":"Chen","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/0300060517703573","article-title":"Pseudomonas aeruginosa prevalence, antibiotic resistance and antimicrobial use in Chinese burn wards from 2007 to 2014","volume":"45","author":"Dou","year":"2017","journal-title":"J. Int. Med. Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0305-4179(02)00024-4","article-title":"Frequency of Pseudomonas aeruginosa serotypes in burn wound infections and their resistance to antibiotics","volume":"28","author":"Estahbanati","year":"2002","journal-title":"Burns"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.burns.2014.10.014","article-title":"The analysis of distribution of multidrug resistant Pseudomonas and Bacillus species from burn patients and burn ward environment","volume":"41","author":"Panghal","year":"2015","journal-title":"Burns"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0305-4179(00)00048-6","article-title":"Nosocomial infections in an Iranian burn care center","volume":"26","author":"Lari","year":"2000","journal-title":"Burns"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0305-4179(00)00086-3","article-title":"Microbiologic aspects of predominant bacteria isolated from the burn patients in Korea","volume":"27","author":"Song","year":"2001","journal-title":"Burns"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1097\/01.PCC.0000161577.27849.BE","article-title":"Sepsis in pediatric burn patients","volume":"6","author":"Sheridan","year":"2005","journal-title":"Pediatr. Crit. Care Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12016-021-08881-2","article-title":"Novel Genetic Discoveries in Primary Immunodeficiency Disorders","volume":"63","author":"Redmond","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/INF.0000000000000550","article-title":"Deficiency of interleukin-1 receptor-associated kinase 4 presenting as fatal Pseudomonas aeruginosa bacteremia in two siblings","volume":"34","author":"Stergiopoulou","year":"2015","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_150","first-page":"357","article-title":"Exome sequencing reveals primary immunodeficiencies in children with community-acquired Pseudomonas aeruginosa sepsis","volume":"7","author":"Asgari","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/MD.0b013e3181fd8ec3","article-title":"Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency","volume":"89","author":"Picard","year":"2010","journal-title":"Medicine"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamapediatrics.2015.2466","article-title":"A child with septic shock and purpura","volume":"170","author":"Flinn","year":"2016","journal-title":"JAMA Pediatr."},{"key":"ref_153","first-page":"54","article-title":"Primary immunodeficiency diseases: An update on the classification from the international union of immunological societies expert committee for primary immunodeficiency","volume":"2","author":"Bousfiha","year":"2011","journal-title":"Front. Immunol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21767\/2172-0479.100099","article-title":"A review on drug testing in animals","volume":"7","author":"Prasad","year":"2016","journal-title":"Transl. Biomed."},{"key":"ref_155","first-page":"453","article-title":"A rat model of chronic respiratory infection with Pseudomonas aeruginosa","volume":"119","author":"Cash","year":"1979","journal-title":"Am. Rev. Resp. Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1258\/002367702320162405","article-title":"Murine models of chronic Pseudomonas aeruginosa lung infection","volume":"36","author":"Schluchter","year":"2002","journal-title":"Lab. Anim."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1128\/IAI.67.7.3625-3630.1999","article-title":"Pseudomonas aeruginosa gene products PilT and PilU are required for cytotoxicity in vitro and virulence in a mouse model of acute pneumonia","volume":"67","author":"Comolli","year":"1999","journal-title":"Infect. Immun."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"S750","DOI":"10.1093\/ofid\/ofz360.1882","article-title":"2202. Validation of a Rabbit Model of Pseudomonas aeruginosa Acute Pneumonia","volume":"6","author":"Gras","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e02724-02720","DOI":"10.1128\/AAC.02724-20","article-title":"Pseudomonas aeruginosa ventilator-associated pneumonia rabbit model for preclinical drug development","volume":"65","author":"Nguyen","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/ALN.0000000000000222","article-title":"A novel porcine model of ventilator-associated pneumonia caused by oropharyngeal challenge with Pseudomonas aeruginosa","volume":"120","author":"Rigol","year":"2014","journal-title":"Anesthesiology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cvsm.2019.10.007","article-title":"Bacterial pneumonia in dogs and cats: An update","volume":"50","author":"Dear","year":"2020","journal-title":"Vet. Clin. Small Anim. Pract."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/path.1700890110","article-title":"The Fate of Pseudontonas aeruginosa, Proteus mirabilis and Escherichia coli in the Mouse Kidney","volume":"89","author":"Gorrill","year":"1965","journal-title":"J. Pathol. Bacteriol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/path.1700640417","article-title":"Bacterial localisation in the kidney with particular reference to Pseudomonas pyocyanea","volume":"64","author":"Gorrill","year":"1952","journal-title":"J. Pathol. Bacteriol."},{"key":"ref_164","first-page":"1079","article-title":"The renal response to infection","volume":"2","author":"Montgomerie","year":"1976","journal-title":"Kidney"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Comber, K. (1976). Pathogenesis of an experimental pyelonephritis model in the mouse and its use in the evaluation of antibiotics. Laboratory Aspects of Infections, Springer.","DOI":"10.1007\/978-1-4684-7653-8_45"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1128\/iai.22.2.508-515.1978","article-title":"Experimental urinary tract infection with Pseudomonas aeruginosa in mice","volume":"22","author":"Nishi","year":"1978","journal-title":"Infect. Immun."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/path.1700900240","article-title":"Experimental pyelonephritis in rats with a glass bead in the bladder","volume":"90","author":"Rocha","year":"1965","journal-title":"J. Pathol. Bacteriol."},{"key":"ref_168","first-page":"341","article-title":"Experimental pyelonephritis: III. The influence of localized injury in different parts of the kidney on susceptibility to bacillary infection","volume":"30","author":"Rocha","year":"1958","journal-title":"Yale J. Biol. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(17)63481-5","article-title":"Effect of prior bacterial immunization on the pathogenesis of retrograde pyelonephritis","volume":"95","author":"Niijima","year":"1966","journal-title":"J. Urol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/nprot.2009.116","article-title":"A murine model of urinary tract infection","volume":"4","author":"Hung","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Penaranda, C., Chumbler, N.M., and Hung, D.T. (2021). Dual transcriptional analysis reveals adaptation of host and pathogen to intracellular survival of Pseudomonas aeruginosa associated with urinary tract infection. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009534"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"16868","DOI":"10.1038\/s41598-019-53434-5","article-title":"A novel mouse model for septic arthritis induced by Pseudomonas aeruginosa","volume":"9","author":"Jin","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1128\/iai.14.4.982-989.1976","article-title":"Synergistic effect on mortality in mice with murine cytomegalovirus and Pseudomonas aeruginosa, Staphylococcus aureus, or Candida albicans infections","volume":"14","author":"Hamilton","year":"1976","journal-title":"Infect. Immun."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3892\/etm.2014.1631","article-title":"Pseudomonas aeruginosa inhibits the growth of pathogenic fungi: In vitro and in vivo studies","volume":"7","author":"Xu","year":"2014","journal-title":"Exp. Ther. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1128\/AAC.03923-14","article-title":"The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsis","volume":"59","author":"Chahin","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41467-020-14363-4","article-title":"Systemic infection facilitates transmission of Pseudomonas aeruginosa in mice","volume":"11","author":"Bachta","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1084\/jem.20071239","article-title":"Immune recognition of Pseudomonas aeruginosa mediated by the IPAF\/NLRC4 inflammasome","volume":"204","author":"Sutterwala","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1128\/IAI.01404-06","article-title":"Human tear fluid protects against Pseudomonas aeruginosa keratitis in a murine experimental model","volume":"75","author":"Kwong","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1167\/iovs.07-0274","article-title":"Cathelicidin-deficient (Cnlp-\/-) mice show increased susceptibility to Pseudomonas aeruginosa keratitis","volume":"48","author":"Huang","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000069006","article-title":"Pseudomonas aeruginosa keratitis in IL-6-deficient mice","volume":"130","author":"Cole","year":"2003","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Fukuda, K., Ishida, W., Uchiyama, J., Rashel, M., Kato, S.-i., Morita, T., Muraoka, A., Sumi, T., Matsuzaki, S., and Daibata, M. (2012). Pseudomonas aeruginosa keratitis in mice: Effects of topical bacteriophage KPP12 administration. PLoS ONE, 77.","DOI":"10.1371\/journal.pone.0047742"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Ring, J., Hoerr, V., Tuchscherr, L., Kuhlmann, M.T., L\u00f6ffler, B., and Faber, C. (2014). MRI visualization of Staphyloccocus aureus-induced infective endocarditis in mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107179"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1128\/AAC.41.8.1662","article-title":"Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or-resistant Staphylococcus aureus","volume":"41","author":"Entenza","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_184","first-page":"703","article-title":"Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence","volume":"215","author":"Oechslin","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/134.1.1","article-title":"Experimental endocarditis due to Pseudomonas aeruginosa. I. Description of a model","volume":"134","author":"Archer","year":"1976","journal-title":"J. Infect. Dis."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/infdis\/136.3.327","article-title":"Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin","volume":"136","author":"Archer","year":"1977","journal-title":"J. Infect. Dis."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Coates, M., Blanchard, S., and MacLeod, A.S. (2018). Innate antimicrobial immunity in the skin: A protective barrier against bacteria, viruses, and fungi. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007353"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e22090","DOI":"10.1096\/fj.202101019R","article-title":"Therapeutic evaluation of immunomodulators in reducing surgical wound infection","volume":"36","author":"Mahmud","year":"2022","journal-title":"FASEB J."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"122","DOI":"10.22203\/eCM.v042a09","article-title":"Therapeutic assessment of N-formyl-methionyl-leucyl-phenylalanine (fMLP) in reducing periprosthetic joint infection","volume":"41","author":"Hamilton","year":"2021","journal-title":"Eur. Cells Mater."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1213\/ANE.0000000000000650","article-title":"Short-term glycemic control is effective in reducing surgical site infection in diabetic rats","volume":"120","author":"Kroin","year":"2015","journal-title":"Anesth. Analg."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1099\/jmm.0.000295","article-title":"Perioperative high inspired oxygen fraction therapy reduces surgical site infection with Pseudomonas aeruginosa in rats","volume":"65","author":"Kroin","year":"2016","journal-title":"J. Med. Microbiol."},{"key":"ref_192","first-page":"795","article-title":"Local vancomycin effectively reduces surgical site infection at implant site in rodents","volume":"43","author":"Kroin","year":"2018","journal-title":"Reg. Anesth. Pain Med."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/jor.21522","article-title":"Hyperbaric oxygen therapy in a mouse model of implant-associated osteomyelitis","volume":"30","author":"Shandley","year":"2012","journal-title":"J. Orthop. Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/jac\/dkr107","article-title":"Effect of the combination of clarithromycin and amikacin on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection","volume":"66","author":"Cirioni","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"110684","DOI":"10.1016\/j.colsurfb.2019.110684","article-title":"Evidence for inoculum size and gas interfaces as critical factors in bacterial biofilm formation on magnesium implants in an animal model","volume":"186","author":"Rahim","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1086\/662712","article-title":"Outbreak of Pseudomonas aeruginosa surgical site infections after arthroscopic procedures: Texas, 2009","volume":"32","author":"Tosh","year":"2011","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1128\/JCM.00501-08","article-title":"Distribution, organization, and ecology of bacteria in chronic wounds","volume":"46","author":"Jensen","year":"2008","journal-title":"J. Clin. Microbiol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1586\/14787210.2015.1023291","article-title":"Chronic wound infections: The role of Pseudomonas aeruginosa and Staphylococcus aureus","volume":"13","author":"Serra","year":"2015","journal-title":"Expert Rev. Anti. Infect Ther."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Wood, S., Jayaraman, V., Huelsmann, E.J., Bonish, B., Burgad, D., Sivaramakrishnan, G., Qin, S., Dipietro, L.A., Zloza, A., and Zhang, C. (2014). Pro-inflammatory chemokine CCL2 (MCP-1) promotes healing in diabetic wounds by restoring the macrophage response. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091574"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jid.2021.08.428","article-title":"IL-10 Dysregulation Underlies Chemokine Insufficiency, Delayed Macrophage Response, and Impaired Healing in Diabetic Wounds","volume":"142","author":"Roy","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.burns.2008.11.010","article-title":"Pseudomonas pyocyanin inhibits wound repair by inducing premature cellular senescence: Role for p38 mitogen-activated protein kinase","volume":"35","author":"Muller","year":"2009","journal-title":"Burns"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/00004630-199209000-00003","article-title":"Pseudomonas aeruginosa Exotoxin A: Its Role in Retardation of Wound Healing The 1992 Lindberg Award","volume":"13","author":"Heggers","year":"1992","journal-title":"J. Burn Care Rehabil."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1128\/IAI.67.10.5324-5331.1999","article-title":"Expression of the soxR gene of Pseudomonas aeruginosa is inducible during infection of burn wounds in mice and is required to cause efficient bacteremia","volume":"67","author":"Ha","year":"1999","journal-title":"Infect. Immun."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1524-475X.2010.00653.x","article-title":"Contribution of quorum sensing to the virulence of Pseudomonas aeruginosa in pressure ulcer infection in rats","volume":"19","author":"Nakagami","year":"2011","journal-title":"Wound Repair Regen."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1128\/IAI.68.4.1834-1839.2000","article-title":"Impact of siderophore production on Pseudomonas aeruginosa infections in immunosuppressed mice","volume":"68","author":"Takase","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1128\/iai.39.3.1067-1071.1983","article-title":"Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice","volume":"39","author":"Cryz","year":"1983","journal-title":"Infect. Immun."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/infdis\/137.6.764","article-title":"Pathogenesis of Pseudomonas aeruginosa pneumonia during immunosuppression","volume":"137","author":"Pennington","year":"1978","journal-title":"J. Infect. Dis."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.2772657","article-title":"Identification of the cystic fibrosis gene: Chromosome walking and jumping","volume":"245","author":"Rommens","year":"1989","journal-title":"Science"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","article-title":"Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis","volume":"73","author":"Welsh","year":"1993","journal-title":"Cell"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"11828","DOI":"10.1038\/s41598-019-48105-4","article-title":"A BAC transgene expressing human CFTR under control of its regulatory elements rescues Cftr knockout mice","volume":"9","author":"Gawenis","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/S1569-1993(11)60020-9","article-title":"Mouse models of cystic fibrosis: Phenotypic analysis and research applications","volume":"10","author":"Wilke","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ame2.12091","article-title":"Characterization of two rat models of cystic fibrosis\u2014KO and F508del CFTR\u2014Generated by Crispr-Cas9","volume":"2","author":"Dreano","year":"2019","journal-title":"Anim. Model. Exp. Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1172\/JCI34599","article-title":"Adeno-associated virus\u2013targeted disruption of the CFTR gene in cloned ferrets","volume":"118","author":"Sun","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_215","first-page":"158","article-title":"Rabbit models for cystic fibrosis","volume":"51","author":"Xu","year":"2016","journal-title":"Pediatr. Pulmonol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"e123529","DOI":"10.1172\/jci.insight.123529","article-title":"A sheep model of cystic fibrosis generated by CRISPR\/Cas9 disruption of the CFTR gene","volume":"3","author":"Fan","year":"2018","journal-title":"JCI Insight"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1172\/JCI119828","article-title":"Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa","volume":"100","author":"Heeckeren","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1164\/rccm.200506-917OC","article-title":"Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice","volume":"173","author":"Schluchter","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jhep.2008.12.014","article-title":"Are pigs more human than mice?","volume":"50","author":"Elferink","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Ng, H.P., Zhou, Y., Song, K., Hodges, C.A., Drumm, M.L., and Wang, G. (2014). Neutrophil-mediated phagocytic host defense defect in myeloid Cftr-inactivated mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0106813"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"20571","DOI":"10.1073\/pnas.1015281107","article-title":"Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth","volume":"107","author":"Rogan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"29ra31","DOI":"10.1126\/scitranslmed.3000928","article-title":"Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth","volume":"2","author":"Stoltz","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Tamma, P., Aitken, S., and Bonomo, R. (2022). IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 2.0, IDSA.","DOI":"10.1093\/cid\/ciad428"},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Tamma, P., Aitken, S., Bonomo, R., Mathers, A., van Duin, D., and Clancy, C. (2022). IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 1.0, IDSA. A Focus on extended-spectrum \u03b2-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTRP. aeruginosa).","DOI":"10.1093\/cid\/ciac268"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-Lactams and \u03b2-lactamase inhibitors: An overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_226","unstructured":"Pandey, N., and Cascella, M. (2022). Beta lactam antibiotics. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0463.2009.02563.x","article-title":"Beta-lactam antibiotics: From antibiosis to resistance and bacteriology","volume":"118","author":"KONG","year":"2010","journal-title":"Acta Pathol. Microbiol. Immunol. Scand."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1128\/AAC.43.6.1379","article-title":"Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents","volume":"43","author":"Carmeli","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: Past, present, and future","volume":"55","author":"Endimiani","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_230","unstructured":"(2022, November 01). FDA Approves New Antibacterial Drug to Treat Complicated Urinary Tract Infections as Part of Ongoing Efforts to Address Antimicrobial Resistance, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"578823","DOI":"10.3389\/fphar.2020.578823","article-title":"The burden of the serious and difficult-to-treat infections and a new antibiotic available: Cefiderocol","volume":"11","author":"Taheri","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1093\/jac\/dky317","article-title":"Stability and low induction propensity of cefiderocol against chromosomal AmpC \u03b2-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae","volume":"73","author":"Ito","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: A siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"e00031-19","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_237","first-page":"265","article-title":"Detection of multidrug resistant (MDR) and extremely drug resistant (XDR) P. aeruginosa isolated from patients in Tehran, Iran","volume":"10","author":"Saderi","year":"2015","journal-title":"Iran. J. Pathol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00003495-199549040-00008","article-title":"Ceftazidime","volume":"49","author":"Rains","year":"1995","journal-title":"Drugs"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non\u2013\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2147\/IDR.S344165","article-title":"Ceftazidime\/Avibactam and Other Commonly Used Antibiotics Activity Against Enterobacterales and Pseudomonas aeruginosa Isolated in Poland in 2015\u20132019","volume":"15","author":"Pojnar","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_241","doi-asserted-by":"crossref","unstructured":"Daikos, G.L., da Cunha, C.A., Rossolini, G.M., Stone, G.G., Baillon-Plot, N., Tawadrous, M., and Irani, P. (2021). Review of ceftazidime-avibactam for the treatment of infections caused by Pseudomonas aeruginosa. Antibiotics, 10.","DOI":"10.3390\/antibiotics10091126"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"e01379-18","DOI":"10.1128\/AAC.01379-18","article-title":"Mutation-driven evolution of Pseudomonas aeruginosa in the presence of either ceftazidime or ceftazidime-avibactam","volume":"62","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/AAC.04238-14","article-title":"Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: Resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa","volume":"59","author":"Winkler","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1021\/acs.oprd.7b00033","article-title":"Patent review of manufacturing routes to fifth-generation cephalosporin drugs. Part 1, Ceftolozane","volume":"21","author":"Hughes","year":"2017","journal-title":"Org. Process Res. Dev."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"e02085-18","DOI":"10.1128\/mBio.02085-18","article-title":"Deciphering the evolution of cephalosporin resistance to ceftolozane-tazobactam in Pseudomonas aeruginosa","volume":"9","author":"Barnes","year":"2018","journal-title":"mBio"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"e01970-17","DOI":"10.1128\/AAC.01970-17","article-title":"Activity of ceftolozane-tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms","volume":"62","author":"Wi","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: Clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_248","first-page":"S39","article-title":"Ceftolozane\/tazobactam resistance in Pseudomonas aeruginosa","volume":"50","author":"Skoglund","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0025-6196(12)61732-7","article-title":"Imipenem","volume":"66","author":"Hellinger","year":"1991","journal-title":"Mayo Clin. Proc."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00003495-199651010-00008","article-title":"Imipenem\/cilastatin","volume":"51","author":"Balfour","year":"1996","journal-title":"Drugs"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/AAC.39.7.1629","article-title":"The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterial metallo-beta-lactamase enzyme CphA","volume":"39","author":"Keynan","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.2147\/IDR.S224228","article-title":"A clinical review and critical evaluation of Imipenem-Relebactam: Evidence to date","volume":"13","author":"Campanella","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-021-01471-8","article-title":"Imipenem\/cilastatin\/relebactam: A review in Gram-negative bacterial infections","volume":"81","author":"Heo","year":"2021","journal-title":"Drugs"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"120440","DOI":"10.1016\/j.envpol.2022.120440","article-title":"Fluoroquinolone antibiotics: Occurrence, mode of action, resistance, environmental detection, and remediation\u2013A comprehensive review","volume":"315","author":"Bhatt","year":"2022","journal-title":"Environ. Pollut."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40265-015-0384-z","article-title":"Finafloxacin: First global approval","volume":"75","author":"McKeage","year":"2015","journal-title":"Drugs"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"e02317-17","DOI":"10.1128\/AAC.02317-17","article-title":"Explorative randomized phase II clinical study of the efficacy and safety of finafloxacin versus ciprofloxacin for treatment of complicated urinary tract infections","volume":"62","author":"Wagenlehner","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_259","unstructured":"Kanj, S.S., and Sexton, D.J. (2020). Pseudomonas aeruginosa Skin and Soft Tissue Infections, UpToDate. The Charleston Co."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14787210.2018.1489721","article-title":"Delafloxacin: A novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa","volume":"16","author":"Ocheretyaner","year":"2018","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/nyas.12830","article-title":"Mechanisms of drug resistance: Quinolone resistance","volume":"1354","author":"Hooper","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1093\/jac\/dkq375","article-title":"Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance","volume":"65","author":"Emrich","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_263","doi-asserted-by":"crossref","unstructured":"Lungu, I.-A., Moldovan, O.-L., Biri\u0219, V., and Rusu, A. (2022). Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081749"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fmicb.2013.00422","article-title":"Responses of Pseudomonas aeruginosa to antimicrobials","volume":"4","author":"Morita","year":"2014","journal-title":"Front. Microbiol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s10096-019-03590-3","article-title":"Eravacycline, a newly approved fluorocycline","volume":"38","author":"Lee","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40265-019-01067-3","article-title":"Eravacycline: A review in complicated intra-abdominal infections","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/aid2.13216","article-title":"Eravacycline for the treatment of complicated intra-abdominal infections","volume":"8","author":"Wang","year":"2021","journal-title":"Adv. Dig. Med."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_270","unstructured":"Block, M., and Blanchard, D.L. (2022). Aminoglycosides. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"e02165-18","DOI":"10.1128\/AAC.02165-18","article-title":"A systematic review of single-dose aminoglycoside therapy for urinary tract infection: Is it time to resurrect an old strategy?","volume":"63","author":"Goodlet","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"S532","DOI":"10.1093\/ofid\/ofx163.1385","article-title":"Plazomicin versus meropenem for complicated urinary tract infection and acute pyelonephritis: Diagnosis-specific results from the Phase 3 EPIC study","volume":"4","author":"Cloutier","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40265-019-1054-3","article-title":"Plazomicin: A novel aminoglycoside for the treatment of resistant Gram-negative bacterial infections","volume":"79","author":"Eljaaly","year":"2019","journal-title":"Drugs"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJM199306173282403","article-title":"Efficacy of aerosolized tobramycin in patients with cystic fibrosis","volume":"328","author":"Ramsey","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1473-3099(19)30574-2","article-title":"Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): A double-blind, randomised, placebo-controlled, phase 3, superiority trial","volume":"20","author":"Niederman","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/jac\/dkq360","article-title":"Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria","volume":"65","author":"Rattanaumpawan","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.chest.2016.11.026","article-title":"A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS Trial","volume":"151","author":"Kollef","year":"2017","journal-title":"Chest"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/jac\/dkm357","article-title":"Polymyxin B for the treatment of multidrug-resistant pathogens: A critical review","volume":"60","author":"Zavascki","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jinf.2019.06.011","article-title":"Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical","volume":"79","author":"Luque","year":"2019","journal-title":"J. Infect."},{"key":"ref_280","doi-asserted-by":"crossref","unstructured":"Ayoub Moubareck, C. (2020). Polymyxins and bacterial membranes: A review of antibacterial activity and mechanisms of resistance. Membranes, 10.","DOI":"10.3390\/membranes10080181"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/phar.1493","article-title":"Adverse reactions associated with systemic polymyxin therapy","volume":"35","author":"Justo","year":"2015","journal-title":"Pharmacotherapy"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc3995","article-title":"Toxicity of polymyxins: A systematic review of the evidence from old and recent studies","volume":"10","author":"Falagas","year":"2006","journal-title":"Crit. Care"},{"key":"ref_283","doi-asserted-by":"crossref","unstructured":"Nation, R.L., Rigatto, M.H.P., Falci, D.R., and Zavascki, A.P. (2019). Polymyxin acute kidney injury: Dosing and other strategies to reduce toxicity. Antibiotics, 8.","DOI":"10.3390\/antibiotics8010024"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/cid\/ciu213","article-title":"Colistin and polymyxin B: Peas in a pod, or chalk and cheese?","volume":"59","author":"Nation","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1055\/s-0037-1602583","article-title":"Emergence of Antimicrobial Resistance among Pseudomonas aeruginosa: Implications for Therapy","volume":"38","author":"Zhanel","year":"2017","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijantimicag.2015.03.001","article-title":"Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology","volume":"45","author":"Potron","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/s-0034-1396907","article-title":"Pseudomonas aeruginosa: Evolution of antimicrobial resistance and implications for therapy","volume":"36","author":"McCarthy","year":"2015","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.drup.2015.08.002","article-title":"The increasing threat of Pseudomonas aeruginosa high-risk clones","volume":"21","author":"Oliver","year":"2015","journal-title":"Drug Resist. Updates"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: Clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.gendis.2019.04.001","article-title":"Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review","volume":"6","author":"Pachori","year":"2019","journal-title":"Genes Dis."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/IDR.S238811","article-title":"Prevalence and some possible mechanisms of colistin resistance among multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa","volume":"13","author":"Masoud","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1128\/AAC.48.12.4606-4610.2004","article-title":"National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002","volume":"48","author":"Obritsch","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/ja.2014.119","article-title":"Increasing resistance rate to carbapenem among blood culture isolates of Klebsiella pneumoniae, Acinetobacterbaumannii and Pseudomonas aeruginosa in a university-affiliated hospital in China, 2004\u20132011","volume":"68","author":"Zhang","year":"2015","journal-title":"J. Antibiot."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S1473-3099(14)70780-7","article-title":"Global antibiotic consumption 2000 to 2010: An analysis of national pharmaceutical sales data","volume":"14","author":"Gandra","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): A randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1086\/426188","article-title":"Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001\u20132003 tracking resistance in the United States today surveillance studies","volume":"40","author":"Karlowsky","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/2047-2994-3-32","article-title":"Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: A systematic review and meta-analysis","volume":"3","author":"Nathwani","year":"2014","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_298","doi-asserted-by":"crossref","unstructured":"Degli Atti, M.C., Bernaschi, P., Carletti, M., Luzzi, I., Garc\u00eda-Fern\u00e1ndez, A., Bertaina, A., Sisto, A., Locatelli, F., and Raponi, M. (2014). An outbreak of extremely drug-resistant Pseudomonas aeruginosa in a tertiary care pediatric hospital in Italy. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-494"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-015-0926-5","article-title":"An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: Impact of multidrug resistance","volume":"19","author":"Micek","year":"2015","journal-title":"Crit. Care"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1086\/528867","article-title":"Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: Need for international harmonization in terminology","volume":"46","author":"Falagas","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ijantimicag.2006.12.012","article-title":"Pandrug-resistant Gram-negative bacteria: The dawn of the post-antibiotic era?","volume":"29","author":"Falagas","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_302","doi-asserted-by":"crossref","unstructured":"Palavutitotai, N., Jitmuang, A., Tongsai, S., Kiratisin, P., and Angkasekwinai, N. (2018). Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193431"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/0974-777X.192962","article-title":"Prevalence of multidrug-resistant, extensively drug-resistant, and pandrug-resistant Pseudomonas aeruginosa from a tertiary level Intensive Care Unit","volume":"8","author":"Gill","year":"2016","journal-title":"J. Glob. Infect. Dis."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ajic.2016.11.002","article-title":"Nosocomial outbreak of extensively drug-resistant Pseudomonas aeruginosa associated with aromatherapy","volume":"45","author":"Mayr","year":"2017","journal-title":"Am. J. Infect. Control"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13756-018-0370-9","article-title":"Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: A systematic review and meta-analysis","volume":"7","author":"Raman","year":"2018","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1592\/phco.2005.25.10.1353","article-title":"Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: Epidemiology and treatment options","volume":"25","author":"Obritsch","year":"2005","journal-title":"Pharmacotherapy"},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3810\/pgm.2005.01.1571","article-title":"Severe Pseudomonas aeruginosa infections. Tackling the conundrum of drug resistance","volume":"117","author":"Hauser","year":"2005","journal-title":"Postgrad Med."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jgar.2018.10.019","article-title":"Changing drug resistance profile in Pseudomonas aeruginosa infection among HIV patients from 2010\u20132017\u2014A retrospective study","volume":"16","author":"Swathirajan","year":"2018","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1399-3062.2009.00380.x","article-title":"Pseudomonas aeruginosa bacteremia over a 10-year period: Multidrug resistance and outcomes in transplant recipients","volume":"11","author":"Johnson","year":"2009","journal-title":"Transpl. Infect. Dis."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijmm.2015.11.004","article-title":"Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options","volume":"306","author":"Chatterjee","year":"2016","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1054\/drup.2000.0152","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and impact on treatment","volume":"3","author":"Hancock","year":"2000","journal-title":"Drug Resist. Updates"},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/cxo.12621","article-title":"Overview of mechanisms of antibiotic resistance in Pseudomonas aeruginosa: An ocular perspective","volume":"101","author":"Subedi","year":"2017","journal-title":"Clin. Exp. Optom."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/338782","article-title":"Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare?","volume":"34","author":"Livermore","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev.micro.56.012302.160310","article-title":"Function of Pseudomonas porins in uptake and efflux","volume":"56","author":"Hancock","year":"2002","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1128\/jb.174.16.5196-5203.1992","article-title":"Reevaluation, using intact cells, of the exclusion limit and role of porin OprF in Pseudomonas aeruginosa outer membrane permeability","volume":"174","author":"Bellido","year":"1992","journal-title":"J. Bacteriol."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1128\/AAC.43.5.1085","article-title":"Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids","volume":"43","author":"Ochs","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/AAC.45.2.428-432.2001","article-title":"Cross-Resistance between Triclosan and Antibiotics in Pseudomonas aeruginosa Is Mediated by Multidrug Efflux Pumps: Exposure of a Susceptible Mutant Strain to Triclosan Selects nfxB Mutants Overexpressing MexCD-OprJ","volume":"45","author":"Chuanchuen","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1128\/AAC.48.5.1797-1802.2004","article-title":"Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously","volume":"48","author":"Llanes","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/AAC.46.8.2696-2699.2002","article-title":"Extrusion of penem antibiotics by multicomponent efflux systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of Pseudomonas aeruginosa","volume":"46","author":"Okamoto","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13756-019-0533-3","article-title":"Antibiotics versus biofilm: An emerging battleground in microbial communities","volume":"8","author":"Sharma","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(01)05321-1","article-title":"Antibiotic resistance of bacteria in biofilms","volume":"358","author":"Stewart","year":"2001","journal-title":"Lancet"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jbiotec.2014.09.003","article-title":"Antibiotic resistance in Pseudomonas aeruginosa biofilms: Towards the development of novel anti-biofilm therapies","volume":"191","author":"Taylor","year":"2014","journal-title":"J. Biotechnol."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"2475067","DOI":"10.1155\/2016\/2475067","article-title":"Mechanisms of antimicrobial resistance in ESKAPE pathogens","volume":"2016","author":"Santajit","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/femsre\/fux010","article-title":"Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria","volume":"41","author":"Hall","year":"2017","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41579-020-00477-5","article-title":"Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis","volume":"19","author":"Rossi","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1099\/jmm.0.030932-0","article-title":"Role of persister cells in chronic infections: Clinical relevance and perspectives on anti-persister therapies","volume":"60","author":"Fauvart","year":"2011","journal-title":"J. Med. Microbiol."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1128\/AAC.48.7.2659-2664.2004","article-title":"Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms","volume":"48","author":"Borriello","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1128\/AAC.00433-15","article-title":"Contribution of stress responses to antibiotic tolerance in Pseudomonas aeruginosa biofilms","volume":"59","author":"Stewart","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fmicb.2014.00070","article-title":"The role of metabolism in bacterial persistence","volume":"5","author":"Amato","year":"2014","journal-title":"Front. Microbiol."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1128\/AAC.34.6.1273","article-title":"Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa","volume":"34","author":"Yoshida","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.1182749","article-title":"Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa","volume":"327","author":"Srinivas","year":"2010","journal-title":"Science"},{"key":"ref_332","doi-asserted-by":"crossref","unstructured":"Jeukens, J., Boyle, B., Kukavica-Ibrulj, I., Ouellet, M.M., Aaron, S.D., Charette, S.J., Fothergill, J.L., Tucker, N.P., Winstanley, C., and Levesque, R.C. (2014). Comparative genomics of isolates of a Pseudomonas aeruginosa epidemic strain associated with chronic lung infections of cystic fibrosis patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087611"},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/gbe\/evy259","article-title":"The Pseudomonas aeruginosa pan-genome provides new insights on its population structure, horizontal gene transfer, and pathogenicity","volume":"11","author":"Freschi","year":"2019","journal-title":"Genome Biol. Evol."},{"key":"ref_334","doi-asserted-by":"crossref","unstructured":"Uddin, M.J., Dawan, J., Jeon, G., Yu, T., He, X., and Ahn, J. (2020). The role of bacterial membrane vesicles in the dissemination of antibiotic resistance and as promising carriers for therapeutic agent delivery. Microorganisms, 8.","DOI":"10.3390\/microorganisms8050670"},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/AAC.49.2.479-487.2005","article-title":"Aminoglycoside resistance in Pseudomonas aeruginosa","volume":"49","author":"Poole","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"10410","DOI":"10.1038\/ncomms10410","article-title":"Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children","volume":"7","author":"Korpela","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13073-016-0294-z","article-title":"The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation","volume":"8","author":"Langdon","year":"2016","journal-title":"Genome Med."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.drudis.2014.07.005","article-title":"An analysis of FDA-approved drugs for infectious disease: Antibacterial agents","volume":"19","author":"Kinch","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1126\/science.8153624","article-title":"Inactivation of antibiotics and the dissemination of resistance genes","volume":"264","author":"Davies","year":"1994","journal-title":"Science"},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jamcollsurg.2016.10.029","article-title":"American College of Surgeons and Surgical Infection Society: Surgical site infection guidelines, 2016 update","volume":"224","author":"Ban","year":"2017","journal-title":"J. Am. Coll. Surg."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"82S","DOI":"10.1097\/01.AOG.0000533379.96988.6a","article-title":"Antibiotic Prophylaxis in Surgical Sterilization: Following the Recommendations [29g]","volume":"131","author":"Saunders","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2125.2011.03991.x","article-title":"Neurotoxic effects associated with antibiotic use: Management considerations","volume":"72","author":"Grill","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.mito.2013.10.005","article-title":"Side effects of antibiotics during bacterial infection: Mitochondria, the main target in host cell","volume":"16","author":"Singh","year":"2014","journal-title":"Mitochondrion"},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3109\/0886022X.2015.1052949","article-title":"Acute renal failure after high-dose antibiotic bone cement: Case report and review of the literature","volume":"37","author":"James","year":"2015","journal-title":"Ren. Fail."},{"key":"ref_346","doi-asserted-by":"crossref","unstructured":"Balch, A., Wendelboe, A.M., Vesely, S.K., and Bratzler, D.W. (2017). Antibiotic prophylaxis for surgical site infections as a risk factor for infection with Clostridium difficile. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179117"},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jtcvs.2015.09.090","article-title":"Antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery","volume":"151","author":"Poeran","year":"2016","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMra1403772","article-title":"Clostridium difficile infection","volume":"372","author":"Leffler","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1001\/jamainternmed.2013.9763","article-title":"Health care\u2013associated infections: A meta-analysis of costs and financial impact on the US health care system","volume":"173","author":"Zimlichman","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/jac\/dkr009","article-title":"The role of topical antibiotics used as prophylaxis in surgical site infection prevention","volume":"66","author":"McHugh","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2014.02.006","article-title":"Innate immune memory: Towards a better understanding of host defense mechanisms","volume":"29","author":"Quintin","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11908-011-0234-4","article-title":"The role of innate immunity in the host defense against intestinal bacterial pathogens","volume":"14","author":"Sotolongo","year":"2012","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1160\/TH03-11-0720","article-title":"Neutrophil function in the healing wound: Adding insult to injury?","volume":"92","author":"Dovi","year":"2004","journal-title":"Thromb Haemost"},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"ref_356","first-page":"3919","article-title":"The antimicrobial peptides and their potential clinical applications","volume":"11","author":"Lei","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nrmicro1098","article-title":"Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria?","volume":"3","author":"Brogden","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_358","doi-asserted-by":"crossref","unstructured":"Da Silva, J., Leal, E.C., and Carvalho, E. (2021). Bioactive Antimicrobial Peptides as Therapeutic Agents for Infected Diabetic Foot Ulcers. Biomolecules, 11.","DOI":"10.3390\/biom11121894"},{"key":"ref_359","doi-asserted-by":"crossref","unstructured":"Chen, C.H., and Lu, T.K. (2020). Development and challenges of antimicrobial peptides for therapeutic applications. Antibiotics, 9.","DOI":"10.3390\/antibiotics9010024"},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.peptides.2014.09.021","article-title":"Inhibition and destruction of Pseudomonas aeruginosa biofilms by antibiotics and antimicrobial peptides","volume":"62","author":"Dosler","year":"2014","journal-title":"Peptides"},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.3389\/fmicb.2019.03053","article-title":"Mechanism of action of surface immobilized antimicrobial peptides against Pseudomonas aeruginosa","volume":"10","author":"Yasir","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/jac\/dkn393","article-title":"Protective effects of the combination of \u03b1-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection","volume":"62","author":"Cirioni","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"26516","DOI":"10.1073\/pnas.1909585117","article-title":"The antimicrobial peptide ZY4 combats multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii infection","volume":"116","author":"Mwangi","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0966-842X(02)02333-8","article-title":"How do bacteria resist human antimicrobial peptides?","volume":"10","author":"Peschel","year":"2002","journal-title":"Trends Microbiol."},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fmicb.2020.00103","article-title":"Resistance evolution against antimicrobial peptides in Staphylococcus aureus alters pharmacodynamics beyond the MIC","volume":"11","author":"Yu","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/nri2436","article-title":"Viral evasion and subversion of pattern-recognition receptor signalling","volume":"8","author":"Bowie","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1073\/pnas.1109921108","article-title":"Brassinosteroids inhibit pathogen-associated molecular pattern\u2013triggered immune signaling independent of the receptor kinase BAK1","volume":"109","author":"Albrecht","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/nrm1984","article-title":"Bacterial elicitation and evasion of plant innate immunity","volume":"7","author":"Abramovitch","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_369","first-page":"1","article-title":"Perception of pathogenic or beneficial bacteria and their evasion of host immunity: Pattern recognition receptors in the frontline","volume":"6","author":"Boutrot","year":"2015","journal-title":"Front. Plant Sci."},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.chom.2010.06.005","article-title":"Inflammasome inhibition as a pathogenic stealth mechanism","volume":"8","author":"Taxman","year":"2010","journal-title":"Cell Host Microbe"},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"8","DOI":"10.12973\/ejms.2014.102p","article-title":"Neutrophil-to-lymphocyte ratio in diabetes mellitus patients with and without diabetic foot ulcer","volume":"1","author":"Kahraman","year":"2014","journal-title":"Eur. J. Med. Sci."},{"key":"ref_372","doi-asserted-by":"crossref","unstructured":"Serban, D., Papanas, N., Dascalu, A.M., Kempler, P., Raz, I., Rizvi, A.A., Rizzo, M., Tudor, C., Silviu Tudosie, M., and Tanasescu, D. (2021). Significance of neutrophil to lymphocyte ratio (nlr) and platelet lymphocyte ratio (plr) in diabetic foot ulcer and potential new therapeutic targets. Int. J. Low. Extrem. Wounds, 15347346211057742.","DOI":"10.1177\/15347346211057742"},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00430-012-0277-7","article-title":"Pseudomonas aeruginosa biofilms perturb wound resolution and antibiotic tolerance in diabetic mice","volume":"202","author":"Watters","year":"2013","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12941-020-00389-5","article-title":"Bacteriophage therapy against Pseudomonas aeruginosa biofilms: A review","volume":"19","author":"Chegini","year":"2020","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijantimicag.2018.09.004","article-title":"Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review","volume":"53","author":"Kakasis","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0042-6822(57)90093-4","article-title":"Electron microscopical studies of phage multiplication: III. Observation of single cell bursts","volume":"3","author":"Kellenberger","year":"1957","journal-title":"Virology"},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1038\/s41467-022-31837-9","article-title":"Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection","volume":"13","author":"Ferry","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","article-title":"Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient","volume":"47","author":"Law","year":"2019","journal-title":"Infection"},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1128\/AAC.01028-06","article-title":"Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model","volume":"51","author":"McVay","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/s41598-018-37636-x","article-title":"Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model","volume":"9","author":"Cafora","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_381","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/emph\/eoy005","article-title":"Phage treatment of an aortic graft infected with Pseudomonas aeruginosa","volume":"2018","author":"Chan","year":"2018","journal-title":"Evol. Med. Public Health"},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/03009734.2019.1688433","article-title":"Pharmacological limitations of phage therapy","volume":"124","author":"Nilsson","year":"2019","journal-title":"Upsala J. Med. Sci."},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"e24219","DOI":"10.4161\/bact.24219","article-title":"Phage therapy: Should bacterial resistance to phages be a concern, even in the long run?","volume":"3","author":"Jalasvuori","year":"2013","journal-title":"Bacteriophage"},{"key":"ref_384","doi-asserted-by":"crossref","unstructured":"Liu, D., Van Belleghem, J.D., de Vries, C.R., Burgener, E., Chen, Q., Manasherob, R., Aronson, J.R., Amanatullah, D.F., Tamma, P.D., and Suh, G.A. (2021). The safety and toxicity of phage therapy: A review of animal and clinical studies. Viruses, 13.","DOI":"10.20944\/preprints202105.0231.v1"},{"key":"ref_385","doi-asserted-by":"crossref","unstructured":"Jurado-Mart\u00edn, I., Sainz-Mej\u00edas, M., and McClean, S. (2021). Pseudomonas aeruginosa: An audacious pathogen with an adaptable arsenal of virulence factors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063128"},{"key":"ref_386","doi-asserted-by":"crossref","unstructured":"Foulkes, D.M., McLean, K., Haneef, A.S., Fernig, D.G., Winstanley, C., Berry, N., and Kaye, S.B. (2019). Pseudomonas aeruginosa toxin ExoU as a therapeutic target in the treatment of bacterial infections. Microorganisms, 7.","DOI":"10.3390\/microorganisms7120707"},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1039\/C9MD00566H","article-title":"Virulence attenuating combination therapy: A potential multi-target synergy approach to treat Pseudomonas aeruginosa infections in cystic fibrosis patients","volume":"11","author":"Shaw","year":"2020","journal-title":"RSC Med. Chem."},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.tips.2016.05.011","article-title":"Targeting the type three secretion system in Pseudomonas aeruginosa","volume":"37","author":"Anantharajah","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1128\/AAC.02643-14","article-title":"A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models","volume":"58","author":"Warrener","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_390","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00284-020-01909-4","article-title":"Curtailing quorum sensing in Pseudomonas aeruginosa by sitagliptin","volume":"77","author":"Abbas","year":"2020","journal-title":"Curr. Microbiol."},{"key":"ref_391","doi-asserted-by":"crossref","first-page":"110372","DOI":"10.1016\/j.celrep.2022.110372","article-title":"Metabolic reprogramming of Pseudomonas aeruginosa by phage-based quorum sensing modulation","volume":"38","author":"Hendrix","year":"2022","journal-title":"Cell Rep."},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrmicro2199","article-title":"The type III secretion system of Pseudomonas aeruginosa: Infection by injection","volume":"7","author":"Hauser","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_393","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.mib.2008.12.007","article-title":"Role of Pseudomonas aeruginosa type III effectors in disease","volume":"12","author":"Engel","year":"2009","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_394","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/21505594.2020.1776979","article-title":"Attenuation of Pseudomonas aeruginosa infection by INP0341, a salicylidene acylhydrazide, in a murine model of keratitis","volume":"11","author":"Sharma","year":"2020","journal-title":"Virulence"},{"key":"ref_395","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1286-4579(00)01327-7","article-title":"The role of quorum sensing in the in vivo virulence of Pseudomonas aeruginosa","volume":"2","author":"Rumbaugh","year":"2000","journal-title":"Microbes Infect."},{"key":"ref_396","doi-asserted-by":"crossref","unstructured":"Saqr, A.A., Aldawsari, M.F., Khafagy, E.-S., Shaldam, M.A., Hegazy, W.A., and Abbas, H.A. (2021). A novel use of Allopurinol as a quorum-sensing inhibitor in Pseudomonas aeruginosa. Antibiotics, 10.","DOI":"10.3390\/antibiotics10111385"},{"key":"ref_397","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.micpath.2018.05.046","article-title":"Developments in strategies for Quorum Sensing virulence factor inhibition to combat bacterial drug resistance","volume":"121","author":"Haque","year":"2018","journal-title":"Microb. Pathog."},{"key":"ref_398","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1080\/21505594.2018.1489198","article-title":"Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice","volume":"9","author":"Sandri","year":"2018","journal-title":"Virulence"},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1080\/17460441.2020.1803274","article-title":"Novel therapeutic strategies for treating Pseudomonas aeruginosa infection","volume":"15","author":"Shao","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_400","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/S0008-6215(03)00312-4","article-title":"Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen","volume":"338","author":"Pier","year":"2003","journal-title":"Carbohydr. Res."},{"key":"ref_401","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0928-8244(03)00094-4","article-title":"Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: Comparison of a systemic vs. a mucosal booster schedule","volume":"37","author":"Baumann","year":"2003","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_402","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.vaccine.2003.11.029","article-title":"Recombinant OprF\u2013OprI as a vaccine against Pseudomonas aeruginosa infections","volume":"22","author":"Baumann","year":"2004","journal-title":"Vaccine"},{"key":"ref_403","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/7391","article-title":"Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury","volume":"5","author":"Sawa","year":"1999","journal-title":"Nat. Med."},{"key":"ref_404","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13054-017-1601-9","article-title":"A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients","volume":"21","author":"Rello","year":"2017","journal-title":"Crit. Care"},{"key":"ref_405","doi-asserted-by":"crossref","first-page":"601601","DOI":"10.3389\/fimmu.2020.601601","article-title":"Development of a chimeric vaccine against Pseudomonas aeruginosa based on the Th17-stimulating epitopes of PcrV and AmpC","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_406","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1128\/IAI.72.12.7012-7021.2004","article-title":"Oral vaccination of BALB\/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model","volume":"72","author":"DiGiandomenico","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_407","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/IAI.01139-10","article-title":"Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection","volume":"79","author":"Kamei","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_408","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.vaccine.2018.01.034","article-title":"Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice","volume":"36","author":"Zhang","year":"2018","journal-title":"Vaccine"},{"key":"ref_409","doi-asserted-by":"crossref","first-page":"D646","DOI":"10.1093\/nar\/gkv1227","article-title":"Enhanced annotations and features for comparing thousands of Pseudomonas genomes in the Pseudomonas genome database","volume":"44","author":"Winsor","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_410","doi-asserted-by":"crossref","first-page":"e01366-15","DOI":"10.1128\/genomeA.01366-15","article-title":"Genome sequences of three strains of the Pseudomonas aeruginosa PA7 clade","volume":"3","author":"Boukerb","year":"2015","journal-title":"Genome Announc."},{"key":"ref_411","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.chom.2014.01.003","article-title":"A type III secretion negative clinical strain of Pseudomonas aeruginosa employs a two-partner secreted exolysin to induce hemorrhagic pneumonia","volume":"15","author":"Elsen","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref_412","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.vaccine.2009.10.080","article-title":"Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: A clinical trial of immunogenicity in lower airways of human volunteers","volume":"28","author":"Bumann","year":"2010","journal-title":"Vaccine"},{"key":"ref_413","doi-asserted-by":"crossref","unstructured":"Killough, M., Rodgers, A.M., and Ingram, R.J. (2022). Pseudomonas aeruginosa: Recent Advances in Vaccine Development. Vaccines, 10.","DOI":"10.3390\/vaccines10071100"},{"key":"ref_414","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1155\/MBD.1994.467","article-title":"Antibacterial silver","volume":"1","author":"Clement","year":"1994","journal-title":"Met.-Based Drugs"},{"key":"ref_415","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.2147\/IJN.S246764","article-title":"The antibacterial mechanism of silver nanoparticles and its application in dentistry","volume":"15","author":"Yin","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_416","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1600-0463.2007.apm_646.x","article-title":"Silver against Pseudomonas aeruginosa biofilms","volume":"115","author":"Bjarnsholt","year":"2007","journal-title":"Acta Pathol. Microbiol. Immunol. Scand."},{"key":"ref_417","first-page":"661","article-title":"The effect of silver nanoparticles on wounds contaminated with Pseudomonas aeruginosa in mice: An experimental study","volume":"16","author":"Ahmadi","year":"2017","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_418","doi-asserted-by":"crossref","first-page":"9050","DOI":"10.1021\/acsami.9b21815","article-title":"Alginate lyase guided silver nanocomposites for eradicating Pseudomonas aeruginosa from lungs","volume":"12","author":"Wan","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_419","doi-asserted-by":"crossref","first-page":"100183","DOI":"10.1016\/j.wndm.2020.100183","article-title":"Healing of Pseudomonas aeruginosa-infected wounds in diabetic db\/db mice by weakly acidic hypochlorous acid cleansing and silver nanoparticle\/chitin-nanofiber sheet covering","volume":"28","author":"Kuwabara","year":"2020","journal-title":"Wound Med."},{"key":"ref_420","doi-asserted-by":"crossref","first-page":"e2390","DOI":"10.1097\/GOX.0000000000002390","article-title":"Silver in wound care\u2014Friend or foe?: A comprehensive review","volume":"7","author":"Khansa","year":"2019","journal-title":"Plast. Reconstr. Surg. Glob. Open"},{"key":"ref_421","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0002-9343(99)80313-1","article-title":"A large randomized clinical trial of a silver-impregnated urinary catheter: Lack of efficacy and staphylococcal superinfection","volume":"98","author":"Riley","year":"1995","journal-title":"Am. J. Med."},{"key":"ref_422","unstructured":"Majno, G. (1991). The Healing Hand: Man and Wound in the Ancient World, Harvard University Press."},{"key":"ref_423","doi-asserted-by":"crossref","first-page":"2464507","DOI":"10.1155\/2019\/2464507","article-title":"Antibacterial potency of honey","volume":"2019","author":"Albaridi","year":"2019","journal-title":"Int. J. Microbiol."},{"key":"ref_424","doi-asserted-by":"crossref","unstructured":"Yupanqui Mieles, J., Vyas, C., Aslan, E., Humphreys, G., Diver, C., and Bartolo, P. (2022). Honey: An Advanced Antimicrobial and Wound Healing Biomaterial for Tissue Engineering Applications. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081663"},{"key":"ref_425","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.arcmed.2005.03.038","article-title":"Bactericidal activity of different honeys against pathogenic bacteria","volume":"36","author":"Lusby","year":"2005","journal-title":"Arch. Med. Res."},{"key":"ref_426","doi-asserted-by":"crossref","first-page":"18160","DOI":"10.1038\/s41598-019-54576-2","article-title":"Honey can inhibit and eliminate biofilms produced by Pseudomonas aeruginosa","volume":"9","author":"Lu","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_427","doi-asserted-by":"crossref","first-page":"e00106-20","DOI":"10.1128\/msystems.00106-20","article-title":"Characterizing the mechanism of action of an ancient antimicrobial, Manuka honey, against Pseudomonas aeruginosa using modern transcriptomics","volume":"5","author":"Bouzo","year":"2020","journal-title":"MSystems"},{"key":"ref_428","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2648.2008.04923.x","article-title":"Standardized antibacterial honey (Medihoney\u2122) with standard therapy in wound care: Randomized clinical trial","volume":"65","author":"Robson","year":"2009","journal-title":"J. Adv. Nurs."},{"key":"ref_429","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.biopha.2018.10.142","article-title":"Hyperbaric oxygen therapy: Antimicrobial mechanisms and clinical application for infections","volume":"109","author":"Memar","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_430","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1586\/eri.09.76","article-title":"Hyperbaric oxygen therapy as an anti-infective agent","volume":"7","author":"Uzun","year":"2009","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_431","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jcf.2019.01.005","article-title":"Hyperbaric oxygen treatment increases killing of aggregating Pseudomonas aeruginosa isolates from cystic fibrosis patients","volume":"18","author":"Jensen","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_432","first-page":"21","article-title":"Effect of hyperbaric oxygen therapy in experimental subcutaneous and pulmonary infections due to Pseudomonas aeruginosa","volume":"26","author":"Luongo","year":"1999","journal-title":"Undersea Hyperb. Med."},{"key":"ref_433","first-page":"CD004123","article-title":"Hyperbaric oxygen therapy for chronic wounds","volume":"2015","author":"Kranke","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_434","doi-asserted-by":"crossref","first-page":"208e","DOI":"10.1097\/01.prs.0000436849.79161.a4","article-title":"Does hyperbaric oxygen therapy work in facilitating acute wound healing: A systematic review","volume":"133","author":"Dauwe","year":"2014","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_435","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1177\/000313481708301031","article-title":"Efficacy of negative pressure wound treatment in preventing surgical site infections after Whipple procedures","volume":"83","author":"Gupta","year":"2017","journal-title":"Am. Surg."},{"key":"ref_436","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.hpb.2017.05.004","article-title":"The use of negative pressure wound therapy to prevent post-operative surgical site infections following pancreaticoduodenectomy","volume":"19","author":"Burkhart","year":"2017","journal-title":"HPB"},{"key":"ref_437","doi-asserted-by":"crossref","unstructured":"Liu, Y., Zhou, Q., Wang, Y., Liu, Z., Dong, M., Wang, Y., Li, X., and Hu, D. (2014). Negative pressure wound therapy decreases mortality in a murine model of burn-wound sepsis involving Pseudomonas aeruginosa infection. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090494"},{"key":"ref_438","first-page":"9496183","article-title":"Negative-pressure wound therapy in a Pseudomonas aeruginosa infection model","volume":"2018","author":"Wang","year":"2018","journal-title":"BioMed Res. Int."},{"key":"ref_439","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s10482-018-1045-5","article-title":"Negative pressure wound therapy reduces the motility of Pseudomonas aeruginosa and enhances wound healing in a rabbit ear biofilm infection model","volume":"111","author":"Guoqi","year":"2018","journal-title":"Antonie Leeuwenhoek"},{"key":"ref_440","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1128\/IAI.67.7.3625-3630.1999","article-title":"PilU and PilT are required for cytotoxicity and virulence of Pseudomonas aeruginosa","volume":"67","author":"Comolli","year":"1999","journal-title":"Infect. Immun."},{"key":"ref_441","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1055\/a-1150-2372","article-title":"Pseudomonas aeruginosa as the main causative agent of osteomyelitis and its susceptibility to antibiotics","volume":"70","author":"Pliska","year":"2020","journal-title":"Drug Res."},{"key":"ref_442","doi-asserted-by":"crossref","first-page":"513242","DOI":"10.3389\/fmed.2020.513242","article-title":"Pseudomonas aeruginosa implant-associated bone and joint infections: Experience in a regional reference center in France","volume":"7","author":"Cerioli","year":"2020","journal-title":"Front. Med."},{"key":"ref_443","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/infdis\/141.1.71","article-title":"Experimental osteomyelitis caused by Pseudomonas aeruginosa","volume":"141","author":"Norden","year":"1980","journal-title":"J. Infect. Dis."},{"key":"ref_444","doi-asserted-by":"crossref","unstructured":"G\u00fcrtler, N., Osthoff, M., Rueter, F., W\u00fcthrich, D., Zimmerli, L., Egli, A., and Bassetti, S. (2019). Prosthetic valve endocarditis caused by Pseudomonas aeruginosa with variable antibacterial resistance profiles: A diagnostic challenge. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4164-3"},{"key":"ref_445","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1378\/chest.09-0132","article-title":"Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005","volume":"136","author":"Razvi","year":"2009","journal-title":"Chest"},{"key":"ref_446","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3201\/eid0802.010163","article-title":"Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada","volume":"8","author":"Speert","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"ref_447","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1378\/chest.15-0676","article-title":"Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis","volume":"149","author":"Salsgiver","year":"2016","journal-title":"Chest"},{"key":"ref_448","doi-asserted-by":"crossref","unstructured":"Dowd, S.E., Callaway, T.R., Wolcott, R.D., Sun, Y., McKeehan, T., Hagevoort, R.G., and Edrington, T.S. (2008). Evaluation of the bacterial diversity in the feces of cattle using 16S rDNA bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP). BMC Microbiol., 8.","DOI":"10.1186\/1471-2180-8-125"},{"key":"ref_449","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.mayocpiqo.2022.04.005","article-title":"Pseudomonal Diabetic Foot Infections: Vive la Diff\u00e9rence?","volume":"6","author":"Lebowitz","year":"2022","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"ref_450","doi-asserted-by":"crossref","first-page":"605195","DOI":"10.1155\/2011\/605195","article-title":"Antimicrobial susceptibility patterns of Pseudomonas aeruginosa from diabetes patients with foot ulcers","volume":"2011","author":"Sivanmaliappan","year":"2011","journal-title":"Int. J. Microbiol."},{"key":"ref_451","first-page":"8","article-title":"Microbial pattern of soft tissue infections in diabetic patients in South India","volume":"5","author":"Dhanasekaran","year":"2003","journal-title":"Asian J. Diabet."},{"key":"ref_452","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0305-4179(89)90182-4","article-title":"Assessment of topical therapy of the burn wound with silver sulphadiazine after its use for 15 years in a burn unit","volume":"15","author":"Koo","year":"1989","journal-title":"Burns"},{"key":"ref_453","doi-asserted-by":"crossref","first-page":"100764","DOI":"10.1016\/j.nmni.2020.100764","article-title":"Epidemiology of burn wound bacterial infections at a Meknes hospital, Morocco","volume":"38","author":"Barguigua","year":"2020","journal-title":"New Microbes New Infect."},{"key":"ref_454","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2147\/IDR.S249160","article-title":"Three year study of infection profile and antimicrobial resistance pattern from burn patients in southwest Iran","volume":"13","author":"Emami","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_455","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-1-4615-0433-7_7","article-title":"Pseudomonas aeruginosa infections in cancer patients","volume":"Volume 7","author":"Hauser","year":"2003","journal-title":"Severe infections caused by Pseudomonas aeruginosa"},{"key":"ref_456","doi-asserted-by":"crossref","first-page":"112829","DOI":"10.1016\/j.ejmech.2020.112829","article-title":"\u03b2-lactam antibiotics: An overview from a medicinal chemistry perspective","volume":"208","author":"Lima","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_457","doi-asserted-by":"crossref","first-page":"1800141","DOI":"10.1002\/ardp.201800141","article-title":"Recent updates of fluoroquinolones as antibacterial agents","volume":"351","author":"Ezelarab","year":"2018","journal-title":"Arch. Pharm."},{"key":"ref_458","doi-asserted-by":"crossref","first-page":"a025387","DOI":"10.1101\/cshperspect.a025387","article-title":"Tetracycline antibiotics and resistance","volume":"6","author":"Grossman","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_459","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1515\/hsz-2013-0292","article-title":"Tetracycline antibiotics and resistance mechanisms","volume":"395","author":"Nguyen","year":"2014","journal-title":"Biol. Chem."},{"key":"ref_460","first-page":"22","article-title":"Mechanisms of antibiotic resistance in Pseudomonas aeruginosa","volume":"95","author":"Lambert","year":"2002","journal-title":"J. R. Soc. Med."},{"key":"ref_461","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1044\/2021_AJA-21-00006","article-title":"Mechanisms of aminoglycoside-and cisplatin-induced ototoxicity","volume":"30","author":"Steyger","year":"2021","journal-title":"Am. J. Audiol."},{"key":"ref_462","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2146\/ajhp060473","article-title":"Polymyxin antibiotics for gram-negative infections","volume":"64","author":"Arnold","year":"2007","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_463","doi-asserted-by":"crossref","first-page":"a025288","DOI":"10.1101\/cshperspect.a025288","article-title":"Polymyxin: Alternative mechanisms of action and resistance","volume":"6","author":"Trimble","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/1\/199\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:57:58Z","timestamp":1760119078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/1\/199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":463,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cells12010199"],"URL":"https:\/\/doi.org\/10.3390\/cells12010199","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,3]]}}}